Saturday, November 12, 2016

AASLD 2016 - Sofosbuvir + Ribavirin Effective in Teens With HCV GT 2/3 

AASLD Coverage @ MPR

Nov 12
Durable SVR12 Seen With Daclatasvir-Based Regimens for HCV
Long-term follow-up data show that sustained virologic response (SVR) at 12 weeks achieved with daclatasvir (DCV)-based regimens are durable in patients with chronic hepatitic C virus (HCV) infection, study authors reported at The Liver Meeting® 2016.
In addition, progression of liver disease or hepatocellular carcinoma are infrequent.

Does Concomitant PPI Use Affect Efficacy of Elbasvir/Grazoprevir?
Consistent concomitant use of proton pump inhibitors (PPIs) with elbasvir/grazoprevir (EBR/GZR) had no clinically significant effect on 12-week sustained viral response (SVR12) rates in patients with hepatitis C virus (HCV) genotype (GT)1 or GT4 infection with and without cirrhosis, according to research presented at The Liver Meeting® 2016.

Viral Response to DAAs Linked to Diabetes Control
Among patients with diabetes, HBA1c significantly improved with hepatitis C virus (HCV) clearance, a retrospective cohort study presented at The Liver Meeting® 2016 concluded.

High SVR Rates With LDV/SOF in 'Real World' HIV/HCV Co-infected Cohorts
Ledipasvir/sofosbuvir therapy for patients with HIV/HCV co-infection is comparably effective in real-world clinical settings and clinical trials.

Sofosbuvir + Ribavirin Effective in Teens With HCV GT 2/3
For adolescents with chronic hepatitis C virus (HCV) infection, treatment with sofosbuvir (SOF) and ribavirin (RBV) led to a 98% SVR12 rate with no virologic failures, reported Kathleen B. Schwarz, MD, a professor of pediatrics at Johns Hopkins University School of Medicine, Baltimore, MD, at The Liver Meeting® 2016.

Significant QoL Improvement With LDV/SOF in Adolescents With HCV GT1
Ledipasvir plus sofosbuvir treatment improved HCV-positive adolescents' quality of life during and after achieving sustained virologic response.

6-Week SOF/LDV Therapy Found Effective in Acute HCV Genotype 1
At The Liver Meeting® 2016, scientists reported that treatment with ledipasvir/sofosbuvir (LDV/SOF) for 6 weeks was well tolerated and highly effective in patients with acute hepatitis C virus (HCV) GT 1 infection.

Chronic Liver Diseases Now Affect 25% of U.S. Adolescents, Young Adults
The prevalence of chronic liver diseases has more than doubled in the past 30 years among adolescents and young adults in the United States to about 25%, according to research presented at The Liver Meeting® 2016.

Sustained SVR With Sofosbuvir-Based Regimens in Chronic HCV With Cirrhosis Confirmed
"Preliminary data from this ongoing observational study of SOF-treated patients with cirrhosis who have achieved SVR show SVR maintained in >99% of patients with a median follow-up of 21 months from the end of treatment," reported Andrew J. Muir, MD, of Duke University in Durham, NC.

AASLD Additional Reading - AASLD 2016 - Large Study Identifies Increase of Cirrhosis in Hepatitis C Patients

DAAs: Exemplary Safety Profile Confirmed Across Broad Population
Direct-acting antiviral (DAA) therapy "has an exemplary safety profile across a broad population of patients treated in usual clinical practice," reported study authors at The Liver Meeting® 2016.

First Oral Pentamidine Isethionate Safe, Well Tolerated for Early Stage HCC
The investigational oral pentamidine isethionate formulation VLX103 is safe and well tolerated at the once-daily 300mg to 900 mg dose.

Regorafenib shows potential utility as a second-line treatment for patients with sorafenib-resistant HCC.

Herbal Tea, Coffee Consumption Tied to Lower Liver Stiffness
Herbal tea and coffee might protect the liver among healthy adults, according to findings presented at The Liver Meeting® 2016.

Tricyclic Antidepressants May Slow Liver Fibrosis Progression, Cirrhosis
Use of tricyclic antidepressants (TCAs) is associated with decreased liver fibrosis progression and delayed time to cirrhosis development, according to a large cohort of veterans with hepatitis C virus (HCV)

Additional updates @ MPR
Current updates: Conference Reports
Updates On This Blog:
AASLD 2016

No comments:

Post a Comment